The pivotal role of real-world data in a pandemic
Drug development for COVID-19 will depend on real-world data and industry is stepping up to implement it
Real-world data is taking on a critical role in the age of COVID-19 drug development, where hasty authorizations are being made on limited datasets and natural history data is being collected in real time.
Teams across the industry have stepped up to adapt their data analysis tools to the crisis with the goal of applying previous learnings to benefit future patients. The challenge now will be scaling their systems to manage the unprecedented volume of patient data, while keeping pace with the evolving pandemic.
Before the pandemic, real-world data (RWD) had been gaining momentum as a tool to create a broader picture of drug safety and efficacy post-market, and to get drugs to market faster under accelerated and conditional approval pathways.
In the context of COVID-19, RWD can help guide clinical trial design and clinical practice, and assist in regulatory decisions.
RWD from COVID-19